• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ACC Roundup: Boston Scientific touts 3-year outcomes for Synergy bioabsorbable drug-eluting stent

March 17, 2017 By Sarah Faulkner

ACC Roundup: Boston Scientific's Synergy drug-eluting stent tops its Promus systemThe team at MassDevice.com and Drug Delivery Business News will be updating this post periodically as news comes out of ACC 2017, the annual American College of Cardiology meeting in Washington March 17-19.

Boston Scientific touts 3-year outcomes for Synergy bioabsorbable drug-eluting stent

ACC Roundup: Boston Scientific touts 3-year outcomes for Synergy bioabsorbable drug-eluting stentData presented at ACC 2017 showed that Boston Scientific‘s (NYSE:BSX) Synergy bioabsorbable polymer drug-eluting stent was as efficacious as the company’s Promus Element Plus drug-eluting stent system, with a lower relative rate of stent thrombosis.

The 3-year Evolve II trial enrolled 1,684 patients with native coronary artery lesions and randomized patients to receive either the Synergy or Promus stent. The primary endpoint was target lesion failure at 12 months.

Previous work has demonstrated that drug-eluting stents reduce cardiac events compared with bare metal stents, but researchers also observed that permanent polymers can cause chronic inflammation and increase the risk of later cardiac events.

The Synergy stent is a thin-strut platinum chromium metal alloy coronary stent. It is made of the same metal alloy as the Promus system, except the Synergy device is coated with an ultrathin abluminal bioresorbable polymer which absorbs completely 3 months after drug elution, according to the researchers.

The data showed that the Synergy stent was non-inferior to the Promus stent for target lesion failure at 1 year. At 2 years, target lesion failure was 9.4% and 8.5% for Synergy and Promus, respectively. Adverse events including death and revascularization were not significantly different between the 2 treatment groups, according to the study.

The researchers observed no additional stent thrombosis events with the Synergy stent beyond day 6 through the 2-year follow-up mark.

Researchers concluded that the Synergy stent, which proved to be as effective as the Promus device, exhibited a low stent thrombosis rate at 1 year, 2 year and 3 years post-implantation.

Pages: Page 1 Page 2 Page 3

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents, Wall Street Beat Tagged With: Boston Scientific, Medtronic

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS